Farmitalia Carlo Erba S.r.l.

Farmitalia Carlo Erba S.p.a.

Pharmacia & Upjohn S.p.a.

Societa' Farmaceutici Italia S.p.a.

Other

Pfizer Italia S.r.l.

Alberto Bargiotti

Antonino Suarato

Sergio Penco

Federico Maria Arcamone

Michele Caruso

Giuseppe Cassinelli

Maria Grandi

Daniela Faiardi

Fernando Giuliani

Pierangelo Zini

Francesco Angelucci

Nicola Mongelli

Ermes Vanotti

Francesco Colotta

Aurelio Di Marco

Roberto D'Alessio

Mario Ferrari

Anna Maria Isetta

Marcellino Tibolla

Annamaria Casazza

Aurelio DIMarco

Maria Gabriella Brasca

Maria Menichincheri

Dario Ballinari

Jacqueline Lansen

Antonella Ermoli

Marina Ripamonti

Cristina Geroni

Anna M Casazza

Teresa Bordoni

Gabriella Pezzoni

Stefania Stefanelli

Nuccia Oneto

Giueseppe Cassinelli

The present invention is directed to compounds of the formula or pharmaceutically acceptable salts, prodrug, solvate or optical isomer thereof, pharmaceutical compositions containing same and use thereof for treating diseases linked to disregulated cell proliferation or to disregulated protein kinase.

Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Benzyloxy prodigiosine compounds

Indolyl-pyrrolydenemethylpyrrole derivatives and process for their

Anthracycline derivatives

Anthracycline glycosides of general formula 1 and 2: ##STR1## wherein R.sub.1 is hydrogen or a methoxy group; R.sub.2 is hydrogen, a hydroxy group or represents an acyloxy residue of formula 3 --O--COR.sub.5 wherein R.sub.5 is a linear or branched C.sub.1 -C.sub.8 alkyl, an aryl group or a heterocyclic mono or bicyclic ring, each of which may be unsubstituted or substituted with (a) an amino group NR.sub.6 R.sub.7 in which R.sub.6 and R.sub.7 are independently hydrogen or C.sub.1 -C.sub.4 alkyl or (b) a carboxy group; R.sub.3 and R.sub.4 both represent hydrogen or one of R.sub.3 and R.sub.4 is hydrogen and the other is hydroxy group or a group of formula --OSO.sub.2 R.sub.8 in which R.sub.8 may be a linear or branched alkyl group containing from 1 to 6 carbon atoms or an aryl group unsubstituted or substituted by 1 to 3 substituents each of which may independently be a linear or branched alkyl or alkoxy group of from 1 to 6 carbon atoms, a halogen atom or a nitro group; and pharmaceutically acceptable salts thereof; are active as antitumor agents.

3'-aziridino-anthracycline derivatives

2-acyloxy-4-morpholinyl anthracyclines

An anthracycline glycoside of general formula 1: ##STR1## wherein R.sub.1 is hydrogen or methoxy group; R.sub.2 is hydrogen or hydroxy group, A and B both represent hydrogen or one of A and B is hydrogen and the other is hydroxy or a group of formula --OSO.sub.2 R.sub.5 in which R.sub.5 is C1-C4 alkyl or aryl optionally substituted by C1-C4 alkyl, nitro, amino, methoxy or halogen; R.sub.3 is a hydrogen atom or a group of formula 2 and R.sub.4 is a group of formula 2

Mono and bis alkylamino-anthracyclines

Anthracycline glycosides having the general formula 1 and 2: ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, fluorine, hydroxy or amino; R.sub.2 and R.sub.3 represent hydroxy or one of R.sub.2 and R.sub.3 is a hydrogen atom, a nitro or an amino group and the other of R.sub.2 and R.sub.3 is a HYDROXY group, exhibit activity against LoVo and LoVo/Dx in vitro.

New 4'-epi-4'-amino anthracyclines

The present invention relates to 3-deoxy-derivatives of D-mannosamine of formula ##STR1## wherein R is --NH.sub.2 or a C.sub.2 -.sub.5 alkanoyl-NH-- or CF.sub.3 CONH-- group; each of R.sub.1 and R.sub.2 independently is C.sub.1 -C.sub.4 alkyl, or R.sub.1 is hydrogen, halogen, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy, and R.sub.2 is hydrogen or both of R.sub.1 and R.sub.2 are fluorine; and wherein, when R.sub.1 is methoxy and R.sub.2 is hydrogen then R is other than --NH.sub.2, or a pharmaceutically acceptable salt thereof, which are useful as angiogenesis inhibitors, in particular as development of metastasis inhibitors.

3-deoxy-mannosamine derivatives

Morpholinyl derivatives of doxorubicin having the general formula A: ##STR1## in which X represents a linear or branched C.sub.2 -C.sub.6 alkyl group or a benzyl group --CH.sub.2 C.sub.6 H.sub.5 and which have (S) or (R) configuration at carbon atom C-2' of the morpholino ring, are antitumor agents.

Morpholinyl derivatives of doxorubicin and process for their preparation

Antitumour anthracycline glycosides of formula I: ##STR1## wherein R.sub.1 is hydrogen or a hydroxyl group, and pharmaceutically acceptable acid addition salts thereof.

4-demethoxy-4'-amino-4'-deoxy-anthracycline derivatives

Anthracycline glycoside compounds of general formula I or II: ##STR1## wherein R.sub.1 is hydrogen or a hydroxy group and R.sub.2 is hydrogen or a methoxy group, and their pharmaceutically acceptable acid addition salts, are antitumor agents.

3'-deamino-4'-deoxy-4'-amino anthracyclines

New anthracycline glycosides having formula: ##STR1## wherein R.sup.1 is hydrogen or hydroxy and either R.sup.2 or R.sup.3 is hydrogen with the other amino-methyl are described. The new compounds and their pharmaceutically acceptable addition salts are useful as antitumour agents.

Antitumor anthracycline glycosides, intermediates thereof, and

Anthracycline glycosides of general formula (I) ##STR1## wherein R is hydrogen or hydroxy, and pharmaceutically acceptable salts thereof, are anti-tumor agents.

3'-deamino-3'-hydroxy-4'-deoxy-4'-amino doxorubicin and related

Anthracycline glycosides of the general formula (A): ##STR1## wherein X is hydrogen or hydroxy and R is hydrogen or a methyl or a hydroxymethyl group; and their pharmaceutically acceptable salts; are useful as antitumor agents.

Morpholino derivatives of daunorubicin and doxorubicin

Growing community of inventors

Milan, Italy

Alberto Bargiotti